MARKET

MCRB

MCRB

Seres Therapeutics Inc
NASDAQ
8.47
+0.25
+3.04%
After Hours: 8.80 +0.33 +3.90% 18:31 02/13 EST
OPEN
8.81
PREV CLOSE
8.22
HIGH
9.97
LOW
8.38
VOLUME
315.50K
TURNOVER
--
52 WEEK HIGH
29.98
52 WEEK LOW
6.53
MARKET CAP
76.62M
P/E (TTM)
14.38
1D
5D
1M
3M
1Y
5Y
1D
Seres Therapeutics (MCRB) Gets a Buy from Canaccord Genuity
TipRanks · 2d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 3d ago
Seres down after pausing investments for lead program
Seeking Alpha · 3d ago
Seres Therapeutics Pauses Key Drug Study, Cuts Jobs To Save Cash
Benzinga · 3d ago
Seres Shares Down After Co Pauses Drug Development, Lays Off Workers
Dow Jones · 3d ago
Seres Therapeutics Finalizes Protocol For Phase 2 Study Of SER-155 In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant With FDA
Benzinga · 3d ago
Seres pauses investment in SER-155 program, reports workforce reduction of 30%
TipRanks · 3d ago
Seres Therapeutics Cuts Workforce by 30% and Shifts Focus to Early-Stage Programs
Reuters · 3d ago
More
About MCRB
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.

Webull offers Seres Therapeutics Inc stock information, including NASDAQ: MCRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MCRB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MCRB stock methods without spending real money on the virtual paper trading platform.